Heart failure in patients with advanced chronic kidney disease

CZecking Heart failure in patients with advanced Chronic Kidney Disease (Czech HF-CKD)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN18275480

Enrollment

300

Registered

2021-03-16

Start date

2019-06-10

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure in patients with advanced chronic kidney disease Circulatory System Hypertensive heart and renal disease

Interventions

This is an observational study of a cohort of patients with advanced chronic kidney disease. The study will collect basic history, clinical assessment of heart failure (HF) symptoms, and use of the “

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Treated by chronic hemodialysis in the collaborating haemodialysis units 2. Clinically stable 3. Willing to participate 4. ESKD treated by hemodialysis for at least 3 months 5. Aged >18 years

Exclusion criteria

Exclusion criteria: 1. Planned kidney transplantation from a living donor within 3 months of the index visit 2. Life expectancy <6 months at the index (first) visit for any reason 3. No dementia

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 07/07/2021: 1. Incidence of cardiovascular death measured from patient notes between baseline and the end of the study 2. Worsening of heart failure (defined as worsening by 1 class of New York Heart Association Functional Classification, the incidence of hospitalization for de-compensation, an ejection fraction decrease by =10%, or new diagnosis of heart failure) measured using clinical assessment and patient notes every 6-12 months between baseline and the end of the study 3. Incidence of significant cardiovascular morbidity (acute coronary syndrome or stroke) measured from patient notes between baseline and the end of the study ______ Previous primary outcome measure: 1. Incidence of death measured from patient notes between baseline and the end of the study 2. Worsening of heart failure (defined as worsening by 1 class of New York Heart Association Functional Classification, the incidence of hospitalization for de-compensation, an ejection fraction decrease by =10%, or new diagnosis of heart failure) measured using clinical assessment and patient notes every 6-12 months between baseline and the end of the study 3. Incidence of significant cardiovascular morbidity (acute coronary syndrome or stroke) measured from patient notes between baseline and the end of the study 4. Coronary or valvular intervention (percutaneous or surgical) measured from patient notes between baseline and the end of the study	—

Measure

Time frame

Current primary outcome measure as of 07/07/2021: 1. Incidence of cardiovascular death measured from patient notes between baseline and the end of the study 2. Worsening of heart failure (defined as worsening by 1 class of New York Heart Association Functional Classification, the incidence of hospitalization for de-compensation, an ejection fraction decrease by =10%, or new diagnosis of heart failure) measured using clinical assessment and patient notes every 6-12 months between baseline and the end of the study 3. Incidence of significant cardiovascular morbidity (acute coronary syndrome or stroke) measured from patient notes between baseline and the end of the study ______ Previous primary outcome measure: 1. Incidence of death measured from patient notes between baseline and the end of the study 2. Worsening of heart failure (defined as worsening by 1 class of New York Heart Association Functional Classification, the incidence of hospitalization for de-compensation, an ejection fraction decrease by =10%, or new diagnosis of heart failure) measured using clinical assessment and patient notes every 6-12 months between baseline and the end of the study 3. Incidence of significant cardiovascular morbidity (acute coronary syndrome or stroke) measured from patient notes between baseline and the end of the study 4. Coronary or valvular intervention (percutaneous or surgical) measured from patient notes between baseline and the end of the study

—

Secondary

Measure	Time frame
Current secondary outcome measures as of 07/07/2021: 1. Components of the primary endpoint measured from patient notes between baseline and the end of the study 2. Incidence of other cardiovascular morbidity (stroke, acute leg ischemia, pulmonary embolism, etc.) measured from patient notes between baseline and the end of the study 3. Need for dry weight decrease by >3% of body weight because of overhydration measured by body composition monitor every 6-12 months between baseline and the end of the study 4. Need of coronary or valvular intervention (percutaneous or surgical) measured from electrocardiography and echocardiography every 6-12 months between baseline and the end of the study 5. Incidence of pacemaker/defibrillator implantation measured from patient notes between baseline and the end of the study 6. Coronary or valvular intervention (percutaneous or surgical) measured from patient notes between baseline and the end of the study 7. Incidence of vascular access intervention measured from patient notes between baseline and the end of the study 8. Non-cardiac death measured from patients notes between baseline and the end of the study _____ Previous secondary outcome measures: 1. Components of the primary endpoint measured from patient notes between baseline and the end of the study 2. Incidence of other cardiovascular morbidity (stroke, acute leg ischemia, pulmonary embolism, etc.) measured from patient notes between baseline and the end of the study 3. Need for dry weight decrease by >3% of body weight because of overhydration measured by body composition monitor every 6-12 months between baseline and the end of the study 4. Need of coronary or valvular intervention (percutaneous or surgical) measured from electrocardiography and echocardiography every 6-12 months between baseline and the end of the study 5. Incidence of pacemaker/defibrillator implantation measured from patient notes between baseline and the end of the study 6. Incidence of vascular	—

Measure

Time frame

Current secondary outcome measures as of 07/07/2021: 1. Components of the primary endpoint measured from patient notes between baseline and the end of the study 2. Incidence of other cardiovascular morbidity (stroke, acute leg ischemia, pulmonary embolism, etc.) measured from patient notes between baseline and the end of the study 3. Need for dry weight decrease by >3% of body weight because of overhydration measured by body composition monitor every 6-12 months between baseline and the end of the study 4. Need of coronary or valvular intervention (percutaneous or surgical) measured from electrocardiography and echocardiography every 6-12 months between baseline and the end of the study 5. Incidence of pacemaker/defibrillator implantation measured from patient notes between baseline and the end of the study 6. Coronary or valvular intervention (percutaneous or surgical) measured from patient notes between baseline and the end of the study 7. Incidence of vascular access intervention measured from patient notes between baseline and the end of the study 8. Non-cardiac death measured from patients notes between baseline and the end of the study _____ Previous secondary outcome measures: 1. Components of the primary endpoint measured from patient notes between baseline and the end of the study 2. Incidence of other cardiovascular morbidity (stroke, acute leg ischemia, pulmonary embolism, etc.) measured from patient notes between baseline and the end of the study 3. Need for dry weight decrease by >3% of body weight because of overhydration measured by body composition monitor every 6-12 months between baseline and the end of the study 4. Need of coronary or valvular intervention (percutaneous or surgical) measured from electrocardiography and echocardiography every 6-12 months between baseline and the end of the study 5. Incidence of pacemaker/defibrillator implantation measured from patient notes between baseline and the end of the study 6. Incidence of vascular

—

Countries

Czech Republic

Contacts

Public ContactAnna Valerianova

anna.valerianova@vfn.cz+420 224 962 363

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 5, 2026